TIDMYGEN

RNS Number : 1841L

Yourgene Health PLC

12 May 2022

Yourgene Health plc

("Yourgene" or the "Company")

CEO share purchase

Director/PDMR Shareholding

Manchester, UK - 12 May 2022: Yourgene (AIM: YGEN), a leading international molecular diagnostics group, announces that it was notified 11 May 2022 that Lyn Rees, Chief Executive Officer of the Company, purchased 1,000,000 (1 million) ordinary shares on 11 May 2022 at a price of 7p per share in his SIPP account.

Following the above transaction, Lyn Rees is interested in 2,037,902 ordinary shares in the Company, representing approximately 0.3 per cent. of the Company's issued share capital.

This announcement contains inside information for the purposes of the UK Market Abuse Regulation.

The Directors of the Company take responsibility for this announcement.

 
Yourgene Health plc                                                   Tel: +44 (0)161 669 8122 
 Lyn Rees, Chief Executive Officer                               investors@yourgene-health.com 
Barry Hextall, Chief Financial Officer 
Joanne Cross, Director of Marketing 
 
Cairn Financial Advisers LLP (NOMAD)                                  Tel: +44 (0)20 7213 0880 
Liam Murray / James Caithie / Ludovico 
 Lazzaretti 
 
Singer Capital Markets (Joint Corporate                               Tel: +44 (0)20 7496 3000 
 Broker) 
Aubrey Powell / Tom Salvesen / George 
 Tzimas 
 
Stifel Nicolaus Europe Limited (Joint                                 Tel: +44 (0)20 7710 7600 
 Corporate Broker) 
Nicholas Moore / Matthew Blawat / Ben 
 Maddison 
 
Walbrook PR Ltd (Media and Investor        Tel: +44 (0)20 7933 8780 or yourgene@walbrookpr.com 
 Relations) 
Paul McManus / Lianne Applegarth                           Mob: 07980 541 893 / Mob: 07584 391 
                                                                                           303 
 
 

About Yourgene Health

Yourgene Health is an international molecular diagnostics group which develops and commercialises genetic products and services. The group works in partnership with global leaders in DNA technology to advance diagnostic science.

Yourgene primarily develops, manufactures, and commercialises simple and accurate molecular diagnostic solutions, for reproductive health, precision medicine and now infectious diseases. The Group's flagship products include non-invasive prenatal tests (NIPT) for Down Syndrome and other genetic disorders, Cystic Fibrosis screening tests, invasive rapid aneuploidy tests, and a recent extension into the oncology space with DPYD genotyping.

The launch of Yourgene Genomic Services has enabled Yourgene to offer a global laboratory service network equipped to be a full life-cycle partner for clinical, research and pharmaceutical organisations to support partners at the preclinical, clinical, and post-market stages to develop, manufacture, obtain regulatory approval and commercialise new products and services. In addition, Yourgene Genomic Services offers an NIPT and high throughput COVID testing service.

In August 2020, Yourgene acquired Coastal Genomics, Inc., a sample preparation technology company based in Vancouver, Canada, enabling the Company to extend its offering and IP portfolio in the DNA sample preparation sector. The acquisition increased Yourgene's geographical penetration into the US and Canada, supplementing existing coverage in the UK, Europe, MEA and Asia.

Yourgene Health is headquartered in Manchester, UK with offices in Taipei, Singapore, the US and Canada, and is listed on the London Stock Exchange's AIM market under the ticker "YGEN". For more information visit www.yourgene-health.com and follow us on twitter @Yourgene_Health.

 
       Details of the person discharging managerial responsibilities 
  1     / person closely associated 
 a)    Name                                     Lyn Rees 
      ---------------------------------------  ---------------------------------- 
       Reason for the notification 
  2 
      --------------------------------------------------------------------------- 
 a)    Position/status                          Chief Executive Officer 
      ---------------------------------------  ---------------------------------- 
 b)    Initial notification                     Initial notification 
        /Amendment 
      ---------------------------------------  ---------------------------------- 
       Details of the issuer, emission allowance market participant, 
  3     auction platform, auctioneer or auction monitor 
      --------------------------------------------------------------------------- 
 a)    Name                                     Yourgene Health plc 
      ---------------------------------------  ---------------------------------- 
 b)    LEI                                      213800UUIT8BZE7QEH33 
      ---------------------------------------  ---------------------------------- 
       Details of the transaction(s): section to be repeated 
  4     for (i) each type of instrument; (ii) each type of transaction; 
        (iii) each date; and (iv) each place where transactions 
        have been conducted 
      --------------------------------------------------------------------------- 
 a)    Description of the                       Ordinary shares of 0.1p each 
        financial instrument, 
        type of instrument 
 
       Identification code                      ISIN: GB00BN31ZD89 
 
 b)    Nature of the transaction                Purchase of ordinary shares 
      ---------------------------------------  ---------------------------------- 
 c)    Price(s) and volume(s) 
                                                --------------  --------------- 
                                                 Price(s)        Volume(s) 
                                                --------------  --------------- 
                                                 7.1p            1,000,000 
                                                --------------  --------------- 
 
 d)    Aggregated information                   N/A 
 
  - Aggregated volume 
 
  - Price 
 
 e)    Date of the transaction                  11 May 2022 
      ---------------------------------------  ---------------------------------- 
 f)    Place of the transaction                 UK 
      ---------------------------------------  ---------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHFZGMKNMLGZZM

(END) Dow Jones Newswires

May 12, 2022 02:02 ET (06:02 GMT)

Yourgene Health (LSE:YGEN)
Historical Stock Chart
From May 2022 to Jun 2022 Click Here for more Yourgene Health Charts.
Yourgene Health (LSE:YGEN)
Historical Stock Chart
From Jun 2021 to Jun 2022 Click Here for more Yourgene Health Charts.